[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Davol, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":78},{"warningLetters":4,"total":77},[5,31,54],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},2675,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2022-05-10T13:20:00Z\">05\u002F10\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-05-02T04:00:00Z\">05\u002F02\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdavid-cosmetic-co-ltd-627408-05022022\">David Cosmetic Co., Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","CGMP\u002FFinished Pharmaceutical\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Kang Wook Lee\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>David Cosmetic Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14 Dodam 8-ro\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Seo-gu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Incheon\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>22667\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Korea\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-22-14\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nMay 2, 2022\u003Cbr>\n\u003Cbr>\nDear Mr. Lee:\u003C\u002Fp>\n\n\u003Cp>Your firm is registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a consumer antiseptic hand rub drug product (also referred to as a consumer hand sanitizer), labeled as CALA Advanced Hand Sanitizer Moisturizing with Aloe Vera Extract. This drug product was manufactured at your facility, David Cosmetic Co., Ltd. at 14 Dodam 8-ro, Seo-gu, Incheon, Republic of Korea, and distributed in the U.S.\u003C\u002Fp>\n\n\u003Cp>The results of the FDA laboratory testing of a batch of this product in U.S. distribution demonstrate that this drug product manufactured at your facility is adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B))\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>, in that contamination with the impurity benzene at unacceptable levels demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>CALA Advanced Hand Sanitizer Moisturizing with Aloe Vera Extract was manufactured at your facility. FDA laboratory testing of a batch of this product in U.S. distribution found that the drug product contained impurities at unacceptable levels. Benzene impurity levels were found to be approximately 6 parts per million (ppm).\u003C\u002Fp>\n\n\u003Cp>Manufacturers should not use benzene in the manufacture of drugs because it is a known human carcinogen that causes leukemia and other blood disorders. FDA has alerted all drug manufacturers to the known risk factors for contamination with benzene. For more information \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fpharmaceutical-quality-resources\u002Ffda-alerts-drug-manufacturers-risk-benzene-contamination-certain-drugs\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fpharmaceutical-quality-resources\u002Ffda-alerts-drug-manufacturers-risk-benzene-contamination-certain-drugs\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>On December 27, 2021, FDA held a teleconference with you. We recommended you consider removing the adulterated batch of CALA Advanced Hand Sanitizer Moisturizing with Aloe Vera Extract currently in distribution from the U.S. market. You committed to recalling the adulterated batch in a December 28, 2021 communication to FDA. In response to FDA’s request during the teleconference for impurity testing results, you responded in a December 29, 2021 communication, stating that you do not conduct impurity testing, including for benzene, of active pharmaceutical ingredients or for your finished hand sanitizer drug products. Because benzene contamination is a known risk of the manufacturing process, a finished product specification for benzene in hand sanitizers is appropriate under 21 CFR 211.160(b). Further, finished product testing of each batch of drug product is required under 21 CFR 211.165. As of the date of this letter, you have yet to initiate a recall.\u003C\u002Fp>\n\n\u003Cp>On January 12, 2022, FDA notified the public of the unacceptable benzene results in your hand sanitizer drugs products at the following website: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed investigation into how the hand sanitizer drug product described above, which was manufactured at your facility contained unacceptable levels of benzene contamination.\u003C\u002Fli>\n\t\u003Cli>A list of all raw materials used to manufacture your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\u003C\u002Fli>\n\t\u003Cli>A list of all batches of any hand sanitizer drug products shipped to the U.S. by your firm, and a full reconciliation of all material you distributed.\u003C\u002Fli>\n\t\u003Cli>Copies of the complete batch records for all batches distributed to the U.S.\u003C\u002Fli>\n\t\u003Cli>Methanol, benzene, acetal, acetaldehyde and test results for all hand sanitizer batches released and distributed.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The contamination with benzene in a drug product manufactured in your facility, in addition to the deficiencies in your response to the information we requested during the December 27, 2021 teleconference, demonstrate that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Note that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on March 10, 2022, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&amp;C Act. Drugs and drug products that appear to be adulterated may be detained or refused admission without physical examination.\u003C\u002Fp>\n\n\u003Cp>All drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the FD&amp;C Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\u003C\u002Fp>\n\n\u003Cp>If you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3015781135 and ATTN: Rory Geyer.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nFrancis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research, FDA\u003Cbr>\n\u003Cbr>\nCC:\u003Cbr>\nRegistered U.S. Agent\u003Cbr>\nYang Ho Dong\u003Cbr>\nOnbix Corporation\u003Cbr>\n102 North G. Street, Unit 105\u003Cbr>\nTacoma, WA 98403-2259\u003Cbr>\nonbixus@gmail.com\u003C\u002Fp>\n\n\u003Cp>____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We note that your drug product also does not conform to any temporary policy FDA has implemented during the public health emergency. In March 2020, the Agency published three guidance documents to provide regulatory flexibility to certain firms to help meet the demand for alcohol-based hand sanitizer during the COVID-19 public health emergency (PHE). Additionally, on December 31, 2021 these guidances were withdrawn, and firms were required to cease distribution, by March 31, 2022, of any remaining hand sanitizer products that were prepared under the temporary policies before or on December 31, 2021. See, 86 FR 56960, October 13, 2021.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Kang Wook Lee\n\nRecipient Title\n\nCEO\n\nDavid Cosmetic Co., Ltd.\n\n14 Dodam 8-ro\n\nSeo-gu\n\nIncheon\n\n22667\n\nSouth Korea\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-22-14\n\nMay 2, 2022\n\nDear Mr. Lee:\n\nYour firm is registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a consumer antiseptic hand rub drug product (also referred to as a consumer hand sanitizer), labeled as CALA Advanced Hand Sanitizer Moisturizing with Aloe Vera Extract. This drug product was manufactured at your facility, David Cosmetic Co., Ltd. at 14 Dodam 8-ro, Seo-gu, Incheon, Republic of Korea, and distributed in the U.S.\n\nThe results of the FDA laboratory testing of a batch of this product in U.S. distribution demonstrate that this drug product manufactured at your facility is adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B))1, in that contamination with the impurity benzene at unacceptable levels demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\n\nAdulteration Violations\n\nCALA Advanced Hand Sanitizer Moisturizing with Aloe Vera Extract was manufactured at your facility. FDA laboratory testing of a batch of this product in U.S. distribution found that the drug product contained impurities at unacceptable levels. Benzene impurity levels were found to be approximately 6 parts per million (ppm).\n\nManufacturers should not use benzene in the manufacture of drugs because it is a known human carcinogen that causes leukemia and other blood disorders. FDA has alerted all drug manufacturers to the known risk factors for contamination with benzene. For more information https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fpharmaceutical-quality-resources\u002Ffda-alerts-drug-manufacturers-risk-benzene-contamination-certain-drugs.\n\nOn December 27, 2021, FDA held a teleconference with you. We recommended you consider removing the adulterated batch of CALA Advanced Hand Sanitizer Moisturizing with Aloe Vera Extract currently in distribution from the U.S. market. You committed to recalling the adulterated batch in a December 28, 2021 communication to FDA. In response to FDA’s request during the teleconference for impurity testing results, you responded in a December 29, 2021 communication, stating that you do not conduct impurity testing, including for benzene, of active pharmaceutical ingredients or for your finished hand sanitizer drug products. Because benzene contamination is a known risk of the manufacturing process, a finished product specification for benzene in hand sanitizers is appropriate under 21 CFR 211.160(b). Further, finished product testing of each batch of drug product is required under 21 CFR 211.165. As of the date of this letter, you have yet to initiate a recall.\n\nOn January 12, 2022, FDA notified the public of the unacceptable benzene results in your hand sanitizer drugs products at the following website: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\n\nIn response to this letter, provide:\n\nA detailed investigation into how the hand sanitizer drug product described above, which was manufactured at your facility contained unacceptable levels of benzene contamination.\n\nA list of all raw materials used to manufacture your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\n\nA list of all batches of any hand sanitizer drug products shipped to the U.S. by your firm, and a full reconciliation of all material you distributed.\n\nCopies of the complete batch records for all batches distributed to the U.S.\n\nMethanol, benzene, acetal, acetaldehyde and test results for all hand sanitizer batches released and distributed.\n\nThe contamination with benzene in a drug product manufactured in your facility, in addition to the deficiencies in your response to the information we requested during the December 27, 2021 teleconference, demonstrate that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&C Act.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nNote that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on March 10, 2022, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&C Act. Drugs and drug products that appear to be adulterated may be detained or refused admission without physical examination.\n\nAll drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the FD&C Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\n\nIf you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3015781135 and ATTN: Rory Geyer.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research, FDA\n\nCC:\n\nRegistered U.S. Agent\n\nYang Ho Dong\n\nOnbix Corporation\n\n102 North G. Street, Unit 105\n\nTacoma, WA 98403-2259\n\nonbixus@gmail.com\n\n____________________\n\n1 We note that your drug product also does not conform to any temporary policy FDA has implemented during the public health emergency. In March 2020, the Agency published three guidance documents to provide regulatory flexibility to certain firms to help meet the demand for alcohol-based hand sanitizer during the COVID-19 public health emergency (PHE). Additionally, on December 31, 2021 these guidances were withdrawn, and firms were required to cease distribution, by March 31, 2022, of any remaining hand sanitizer products that were prepared under the temporary policies before or on December 31, 2021. See, 86 FR 56960, October 13, 2021.","David Cosmetic Co., Ltd.","david-cosmetic-co-ltd-627408-05022022","2026-08-18T06:42:29.262718+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdavid-cosmetic-co-ltd-627408-05022022","2026-10-26T08:08:21.642983+00:00","Warning Letter","Issued","2022-05-10","627408","Drugs","Mr. Kang Wook Lee","2026-08-20T01:55:04.08+00:00","VIA UPS","2022-05-02",{"id":32,"raw":33,"subject":38,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":18,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":46,"posted_date":47,"marcs_cms_no":48,"product_type":49,"closeout_date":50,"issuing_office":37,"recipient_name":51,"body_fetched_at":52,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":53,"medical_device_id":19,"response_letter_date":19},2641,[34,35,36,37,38,13,39,13],"\u003Ctime datetime=\"2022-05-31T13:20:00Z\">05\u002F31\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-04-28T04:00:00Z\">04\u002F28\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fruss-davis-wholesale-inc-628195-04282022\">Russ Davis Wholesale Inc\u003C\u002Fa>","Office of Human and Animal Food Operations - West Division 1","Juice HACCP\u002FCGMP for Foods\u002FAdulterated\u002FInsanitary Conditions","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fruss-davis-wholesale-inc-628195-07132023\">\u003Ctime datetime=\"2023-07-21T04:00:00Z\">07\u002F21\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Adam Gamble\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Russ Davis Wholesale Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>266 NE Fourth Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Wadena\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>56482\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations - West Division 1\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 28, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Refer to CMS 628195\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Gamble:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) inspected your ready-to-eat (RTE) food and beverage facility located at 2805 W. Service Road, Eagan, Minnesota, on December 14-16, 20, and 22, 2021, and January 14 and 19, 2022. Your facility manufactures RTE prepared salads, mixed-commodity food trays, taco dips, heat-and-serve meals, sandwiches and subs, and bottled citrus juice. During our inspection FDA investigators found serious violations of the Juice Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, \u003Cstrong>Code of Federal Regulations\u003C\u002Fstrong>, Part 120 (21 CFR 120) and the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule), Title 21, \u003Cstrong>Code of Federal Regulations\u003C\u002Fstrong>, Part 117 (21 CFR 117). At the conclusion of the inspection the FDA investigators issued a Form FDA-483, Inspectional Observations, listing the deviations found at your facility.\u003C\u002Fp>\n\n\u003Cp>Based on FDA’s inspectional findings, we have determined that the citrus juice and RTE snack products manufactured in your facility are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 United States Code (U.S.C.) § 342(a)(4)] in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP &amp; PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and further information about the CGMP &amp; PC rule through links on FDA's internet home page at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>On January 27, 2022, we received a response to the inspectional observations listed on the Form FDA-483, dated January 19, 2022. Based on our review of the inspectional findings and the response provided by your firm, this letter advises you of FDA’s continuing concerns and provides detailed information describing the findings at your facility.\u003C\u002Fp>\n\n\u003Cp>Your significant violations are as follows:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Juice HACCP (21 CFR Part 120)\u003C\u002Fstrong>\u003Cbr>\n1. Your firm failed to take corrective actions when a deviation from a critical limit occurred during the manufacture of cold pressed citrus juice, as required by 21 CFR 120.10(b). Review of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> recording charts that monitor the \u003Cstrong>(b)(4)\u003C\u002Fstrong> critical limit of your citrus fruit \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;treatment that uses \u003Cstrong>(b)(4)\u003C\u002Fstrong> to achieve a minimum 5-log reduction in the pertinent microorganism, revealed deviations from the critical limits identified in your Juice HACCP plan for cold pressed citrus juice with no corrective actions on\u003Cbr>\nNovember 11, 12, 15, and 16, 2021. On these dates your \u003Cstrong>(b)(4)\u003C\u002Fstrong> charts recorded \u003Cstrong>(b)(4)\u003C\u002Fstrong> your critical limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, but you did not take corrective action. Also, in one instance the \u003Cstrong>(b)(4)\u003C\u002Fstrong> was not working and you did not take corrective action. Additionally, the corrective action listed at CCP \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong> treatment) is “If critical limit for \u003Cstrong>(b)(4)\u003C\u002Fstrong> is not met, \u003Cstrong>(b)(4)\u003C\u002Fstrong> must be reprocessed or disposed of.” This corrective action does not ensure that the cause of the deviation is corrected.\u003C\u002Fp>\n\n\u003Cp>Your response acknowledges the inaccuracy of your continuous monitoring chart recording devices and indicates that your firm has discontinued use of these devices. In their place, you state your intention to monitor the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>To rely on monitoring the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you would need to validate that doing so will ensure compliance with the critical limits identified during the study and update your current Juice HACCP plan for cold pressed citrus juices to account for this change in your procedure. During the inspection, investigators discussed their concern that your current \u003Cstrong>(b)(4)\u003C\u002Fstrong> treatment procedures may not provide a 5-log reduction of the pertinent microorganisms you identify as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>2. You did not validate that your HACCP plan is adequate to control food hazards when a change in the process occurred that could have affected the hazard analysis or altered the HACCP plan in any way, as required by 21 CFR 120.11(b). Specifically, you had an outside laboratory perform a process validation study, dated March 21, 2021, to determine whether the \u003Cstrong>(b)(4)\u003C\u002Fstrong> is an effective \u003Cstrong>(b)(4)\u003C\u002Fstrong> treatment critical control point (CCP) to achieve a minimum 5-log reduction for the control of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The validation concluded that \u003Cstrong>(b)(4)\u003C\u002Fstrong> provides a minimum 5-log reduction in lemons, mandarins, limes, and oranges; a \u003Cstrong>(b)(4)\u003C\u002Fstrong> is required for grapefruit. The validation further stated that verification of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> is an important part of this CCP. Your firm started producing \u003Cstrong>(b)(4)\u003C\u002Fstrong> treated citrus juice in April 2021 without adequate verification of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> treatment as performed at your facility.\u003C\u002Fp>\n\n\u003Cp>The validation study you relied on was done in a laboratory setting with \u003Cstrong>(b)(4)\u003C\u002Fstrong> using a device to monitor the \u003Cstrong>(b)(4)\u003C\u002Fstrong> that been been verified by a \u003Cstrong>(b)(4)\u003C\u002Fstrong>. \u003Cstrong>(b)(4)\u003C\u002Fstrong> pieces of each fruit were used in the study; they were \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>You did not validate that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> treatment process using your \u003Cstrong>(b)(4)\u003C\u002Fstrong> can mimic the laboratory study conditions completed with dissimilar equipment.\u003C\u002Fli>\n\t\u003Cli>The \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> is not \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure \u003Cstrong>(b)(4)\u003C\u002Fstrong> within the \u003Cstrong>(b)(4)\u003C\u002Fstrong> during processing.\u003C\u002Fli>\n\t\u003Cli>A \u003Cstrong>(b)(4)\u003C\u002Fstrong> study was not conducted to identify any \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, so the \u003Cstrong>(b)(4)\u003C\u002Fstrong> can be monitored accurately and effectively under typical and worst-case operating conditions.\u003C\u002Fli>\n\t\u003Cli>You pack the fruit in \u003Cstrong>(b)(4)\u003C\u002Fstrong> such that fruit is pressed against each other and against the \u003Cstrong>(b)(4)\u003C\u002Fstrong> walls. You did not determine if this orientation provides complete \u003Cstrong>(b)(4)\u003C\u002Fstrong> in order to meet the critical limits identified in the study.\u003C\u002Fli>\n\t\u003Cli>The \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring probe that reads to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> display panel is located near the \u003Cstrong>(b)(4)\u003C\u002Fstrong> within \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring device that reads to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> chart is attached to the outside surface of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You did not determine if the installation locations of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and recording devices provide an accurate reading of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> during operating conditions.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your response indicates that you will order equipment (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) and will perform a \u003Cstrong>(b)(4)\u003C\u002Fstrong> study to validate that your equipment and procedures can achieve the critical limits stated in your external validation study. Your response does not include details of the specific equipment and planned procedure for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> study, or who will perform and\u002For oversee the study, and their qualifications.\u003C\u002Fp>\n\n\u003Cp>We remind you that as a citrus juice processor who relies on surface sanitization treatments [21 CFR 120.24(b)], these treatments must consistently achieve at least a 5-log reduction in the pertinent microorganism(s), for a period at least as long as the shelf life of the product when stored under normal and moderate abuse conditions, to comply with 21 CFR 120.24(a). FDA provides juice product industry guidance at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fguidance-industry-juice-hazard-analysis-critical-control-point-hazards-and-controls-guidance-first\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fguidance-industry-juice-hazard-analysis-critical-control-point-hazards-and-controls-guidance-first\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>We also note that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> recording chart that you provided does not contain the name of the product, and it does not list any lot number\u002Fbatch number or other unique identifier that clearly link the record to the product. Processing records must include “…the identity of the product and the production code, if any,” to comply with 21 CFR 120.12(b)(4). Your firm uses production\u002Flot codes on finished juice products, as described in the collected affidavit.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Current Good Manufacturing Practice (Subpart B)\u003C\u002Fstrong>\u003Cbr>\n3. You did not take adequate precautions to ensure that production procedures did not contribute to allergen cross-contact, as required by 21 CFR 117.80(a)(4). Specifically, on December 14, 2021, employees were observed first assembling Protein Powerhouse Snacker (item 81061) which includes hard-cooked egg, red grapes, and cheddar cheese cubes (among other ingredients). Individual ingredients were staged in bins on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Line. \u003Cstrong>(b)(4)\u003C\u002Fstrong> placed hard-cooked egg, red grapes, and cheddar cheese cubes from the bins into finished product trays using the same \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The same bins of red grapes and cheddar cheese cubes were then used to assemble Apple &amp; Cheese Snacker (item 81031) and subsequently Fruit &amp; Cheese Snacker (item 81033), neither of which contains egg. Additionally, on December 20, 2021, investigators observed a bin of dried cranberries that contained several soybeans. Your employees stated the cranberries were staged to be used in Super Kale Salad (item 89330) that did not contain soy.\u003C\u002Fp>\n\n\u003Cp>Your response states that the root cause of this allergen cross-contact was the size of the bin containers. Your response states that the bin containers have been replaced with \u003Cstrong>(b)(4)\u003C\u002Fstrong> and that you plan to \u003Cstrong>(b)(4)\u003C\u002Fstrong> after each product run. However, you did not include updated procedures to account for the production changes or indicate whether employees have been trained on the updated procedures. Additionally, you did not address employee practices which may have led to allergen cross-contact.\u003C\u002Fp>\n\n\u003Cp>Allergen handling has previously been identified as a concern at your facility and was documented in a Form FDA-483 issued to your firm in March 2021 and further discussed during a Regulatory Meeting held with your firm on June 28, 2021. During the discussion you stated that you understood our concerns and that you have implemented corrections.\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure your facility complies with all requirements of federal law, including FDA regulations. You should take prompt action to correct or implement corrections to the violations cited in this letter. Failure to do so may result in legal action without further notice, including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within 15 working days of the receipt of this letter as to the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within 15 working days, state the reason for the delay and the time frame within which you will do so.\u003C\u002Fp>\n\n\u003Cp>Please send your written response to Carolyn Warren, Compliance Officer, U.S. Food and Drug Administration, 250 Marquette Avenue, Suite 600, Minneapolis, Minnesota, 55401. If you have any questions regarding issues in this letter, please contact Ms. Warren at (612) 758-7182.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Michael Dutcher, DVM\u003Cbr>\nDistrict Director, Minneapolis District\u003Cbr>\nProgram Division Director, Office of Human\u003Cbr>\n&nbsp; and Animal Food Operations - West Division 1\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\u003Cp>xc: Ryan M. Briske\u003Cbr>\nPlant Manager\u003Cbr>\nRuss Davis Wholesale Inc.\u003Cbr>\n2805 W. Service Road\u003Cbr>\nEagan, MN 55121-1222\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nAdam Gamble\n\nRecipient Title\n\nPresident and Chief Executive Officer\n\nRuss Davis Wholesale Inc\n\n266 NE Fourth Street\n\nWadena, MN 56482\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations - West Division 1\n\nUnited States\n\nApril 28, 2022\n\nWARNING LETTER\n\nRefer to CMS 628195\n\nDear Mr. Gamble:\n\nThe United States Food and Drug Administration (FDA) inspected your ready-to-eat (RTE) food and beverage facility located at 2805 W. Service Road, Eagan, Minnesota, on December 14-16, 20, and 22, 2021, and January 14 and 19, 2022. Your facility manufactures RTE prepared salads, mixed-commodity food trays, taco dips, heat-and-serve meals, sandwiches and subs, and bottled citrus juice. During our inspection FDA investigators found serious violations of the Juice Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations, Part 120 (21 CFR 120) and the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR 117). At the conclusion of the inspection the FDA investigators issued a Form FDA-483, Inspectional Observations, listing the deviations found at your facility.\n\nBased on FDA’s inspectional findings, we have determined that the citrus juice and RTE snack products manufactured in your facility are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 United States Code (U.S.C.) § 342(a)(4)] in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP & PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and further information about the CGMP & PC rule through links on FDA's internet home page at http:\u002F\u002Fwww.fda.gov.\n\nOn January 27, 2022, we received a response to the inspectional observations listed on the Form FDA-483, dated January 19, 2022. Based on our review of the inspectional findings and the response provided by your firm, this letter advises you of FDA’s continuing concerns and provides detailed information describing the findings at your facility.\n\nYour significant violations are as follows:\n\nJuice HACCP (21 CFR Part 120)\n\n1. Your firm failed to take corrective actions when a deviation from a critical limit occurred during the manufacture of cold pressed citrus juice, as required by 21 CFR 120.10(b). Review of your (b)(4) recording charts that monitor the (b)(4) critical limit of your citrus fruit (b)(4) treatment that uses (b)(4) to achieve a minimum 5-log reduction in the pertinent microorganism, revealed deviations from the critical limits identified in your Juice HACCP plan for cold pressed citrus juice with no corrective actions on\n\nNovember 11, 12, 15, and 16, 2021. On these dates your (b)(4) charts recorded (b)(4) your critical limit of (b)(4), but you did not take corrective action. Also, in one instance the (b)(4) was not working and you did not take corrective action. Additionally, the corrective action listed at CCP (b)(4) ((b)(4) treatment) is “If critical limit for (b)(4) is not met, (b)(4) must be reprocessed or disposed of.” This corrective action does not ensure that the cause of the deviation is corrected.\n\nYour response acknowledges the inaccuracy of your continuous monitoring chart recording devices and indicates that your firm has discontinued use of these devices. In their place, you state your intention to monitor the (b)(4).\n\nTo rely on monitoring the (b)(4), you would need to validate that doing so will ensure compliance with the critical limits identified during the study and update your current Juice HACCP plan for cold pressed citrus juices to account for this change in your procedure. During the inspection, investigators discussed their concern that your current (b)(4) treatment procedures may not provide a 5-log reduction of the pertinent microorganisms you identify as (b)(4), and (b)(4).\n\n2. You did not validate that your HACCP plan is adequate to control food hazards when a change in the process occurred that could have affected the hazard analysis or altered the HACCP plan in any way, as required by 21 CFR 120.11(b). Specifically, you had an outside laboratory perform a process validation study, dated March 21, 2021, to determine whether the (b)(4) is an effective (b)(4) treatment critical control point (CCP) to achieve a minimum 5-log reduction for the control of (b)(4). The validation concluded that (b)(4) provides a minimum 5-log reduction in lemons, mandarins, limes, and oranges; a (b)(4) is required for grapefruit. The validation further stated that verification of the (b)(4) is an important part of this CCP. Your firm started producing (b)(4) treated citrus juice in April 2021 without adequate verification of the (b)(4) treatment as performed at your facility.\n\nThe validation study you relied on was done in a laboratory setting with (b)(4) using a device to monitor the (b)(4) that been been verified by a (b)(4). (b)(4) pieces of each fruit were used in the study; they were (b)(4).\n\nYou did not validate that the (b)(4) treatment process using your (b)(4) can mimic the laboratory study conditions completed with dissimilar equipment.\n\nThe (b)(4) in your (b)(4) is not (b)(4) to ensure (b)(4) within the (b)(4) during processing.\n\nA (b)(4) study was not conducted to identify any (b)(4) in your (b)(4), so the (b)(4) can be monitored accurately and effectively under typical and worst-case operating conditions.\n\nYou pack the fruit in (b)(4) such that fruit is pressed against each other and against the (b)(4) walls. You did not determine if this orientation provides complete (b)(4) in order to meet the critical limits identified in the study.\n\nThe (b)(4) monitoring probe that reads to the (b)(4) display panel is located near the (b)(4) within (b)(4) of the (b)(4). The (b)(4) monitoring device that reads to the (b)(4) chart is attached to the outside surface of the (b)(4). You did not determine if the installation locations of your (b)(4) and recording devices provide an accurate reading of the (b)(4) during operating conditions.\n\nYour response indicates that you will order equipment ((b)(4)) and will perform a (b)(4) study to validate that your equipment and procedures can achieve the critical limits stated in your external validation study. Your response does not include details of the specific equipment and planned procedure for the (b)(4) study, or who will perform and\u002For oversee the study, and their qualifications.\n\nWe remind you that as a citrus juice processor who relies on surface sanitization treatments [21 CFR 120.24(b)], these treatments must consistently achieve at least a 5-log reduction in the pertinent microorganism(s), for a period at least as long as the shelf life of the product when stored under normal and moderate abuse conditions, to comply with 21 CFR 120.24(a). FDA provides juice product industry guidance at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fguidance-industry-juice-hazard-analysis-critical-control-point-hazards-and-controls-guidance-first.\n\nWe also note that the (b)(4) recording chart that you provided does not contain the name of the product, and it does not list any lot number\u002Fbatch number or other unique identifier that clearly link the record to the product. Processing records must include “…the identity of the product and the production code, if any,” to comply with 21 CFR 120.12(b)(4). Your firm uses production\u002Flot codes on finished juice products, as described in the collected affidavit.\n\nCurrent Good Manufacturing Practice (Subpart B)\n\n3. You did not take adequate precautions to ensure that production procedures did not contribute to allergen cross-contact, as required by 21 CFR 117.80(a)(4). Specifically, on December 14, 2021, employees were observed first assembling Protein Powerhouse Snacker (item 81061) which includes hard-cooked egg, red grapes, and cheddar cheese cubes (among other ingredients). Individual ingredients were staged in bins on the (b)(4) Line. (b)(4) placed hard-cooked egg, red grapes, and cheddar cheese cubes from the bins into finished product trays using the same (b)(4). The same bins of red grapes and cheddar cheese cubes were then used to assemble Apple & Cheese Snacker (item 81031) and subsequently Fruit & Cheese Snacker (item 81033), neither of which contains egg. Additionally, on December 20, 2021, investigators observed a bin of dried cranberries that contained several soybeans. Your employees stated the cranberries were staged to be used in Super Kale Salad (item 89330) that did not contain soy.\n\nYour response states that the root cause of this allergen cross-contact was the size of the bin containers. Your response states that the bin containers have been replaced with (b)(4) and that you plan to (b)(4) after each product run. However, you did not include updated procedures to account for the production changes or indicate whether employees have been trained on the updated procedures. Additionally, you did not address employee practices which may have led to allergen cross-contact.\n\nAllergen handling has previously been identified as a concern at your facility and was documented in a Form FDA-483 issued to your firm in March 2021 and further discussed during a Regulatory Meeting held with your firm on June 28, 2021. During the discussion you stated that you understood our concerns and that you have implemented corrections.\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure your facility complies with all requirements of federal law, including FDA regulations. You should take prompt action to correct or implement corrections to the violations cited in this letter. Failure to do so may result in legal action without further notice, including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\n\nPlease notify this office in writing within 15 working days of the receipt of this letter as to the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within 15 working days, state the reason for the delay and the time frame within which you will do so.\n\nPlease send your written response to Carolyn Warren, Compliance Officer, U.S. Food and Drug Administration, 250 Marquette Avenue, Suite 600, Minneapolis, Minnesota, 55401. If you have any questions regarding issues in this letter, please contact Ms. Warren at (612) 758-7182.\n\nSincerely,\n\n\u002FS\u002F\n\nMichael Dutcher, DVM\n\nDistrict Director, Minneapolis District\n\nProgram Division Director, Office of Human\n\nand Animal Food Operations - West Division 1\n\nxc: Ryan M. Briske\n\nPlant Manager\n\nRuss Davis Wholesale Inc.\n\n2805 W. Service Road\n\nEagan, MN 55121-1222","Russ Davis Wholesale Inc","russ-davis-wholesale-inc-628195-04282022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fruss-davis-wholesale-inc-628195-04282022","2026-10-26T08:09:51.769802+00:00","Closed Out","2022-05-31","628195","Food & Beverages","2023-07-21","Adam Gamble","2026-08-20T01:51:46.659+00:00","2022-04-28",{"id":55,"raw":56,"subject":61,"body_html":63,"body_text":64,"firm_name":65,"letter_id":66,"created_at":67,"fei_number":19,"letter_url":68,"updated_at":69,"action_type":22,"case_status":46,"posted_date":70,"marcs_cms_no":71,"product_type":72,"closeout_date":73,"issuing_office":60,"recipient_name":74,"body_fetched_at":75,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":76,"medical_device_id":19,"response_letter_date":19},3272,[57,58,59,60,61,13,62,13],"\u003Ctime datetime=\"2021-07-06T13:20:00Z\">07\u002F06\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-06-25T04:00:00Z\">06\u002F25\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdavati-medical-supply-llc-615530-06252021\">Davati Medical Supply LLC\u003C\u002Fa>","Center for Biologics Evaluation and Research","Unapproved and Misbranded Product Related to Influenza Virus","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdavati-medical-supply-llc-615530-10142021\">\u003Ctime datetime=\"2021-10-14T04:00:00Z\">10\u002F14\u002F2021\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Herman Cardenas\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Davati Medical Supply LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3121 Eagles Nest St., Suite 120\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Round Rock\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>78665\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:contact@davatimedical.com\"> contact@davatimedical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>CBER 21-02\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: June 25, 2021\u003Cbr>\n\u003Cbr>\nRE: Unapproved and Misbranded Product Related to Influenza Virus\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) has reviewed your website at www.davatimedical.com, on June 22, 2021. Your website directs consumers to contact you to purchase FLUZALP® QUADRIVALENT, Influenza Vaccine, which you represent is manufactured by Anzalp Pharmasolutions Pvt. Ltd. The FDA has observed that you offer this influenza vaccine product for sale in the United States and that the product is intended to mitigate, prevent, treat, diagnose, or cure Influenza Virus, commonly referred to as “the Flu”, in people.\u003C\u002Fp>\n\n\u003Cp>Based on our review, this product is an unapproved new drug under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355. Furthermore, this product is a misbranded drug under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of this product into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d).\u003C\u002Fp>\n\n\u003Cp>Your product is also an unlicensed biological product under section 351 of the Public Health Service Act (PHS Act), 42 U.S.C. § 262. In order to lawfully market a drug that is also a biological product, a valid biologics license must be in effect under the PHS Act. 42 U.S.C. § 262(a). Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations. 21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312. Your product is not the subject of an approved biologics license application (BLA) nor is there an IND in effect for your product.\u003C\u002Fp>\n\n\u003Cp>FDA is taking urgent measures to protect consumers from certain products that, without licensure, approval, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure Influenza Virus in people. As described in this letter, you offer for sale a product that is intended to mitigate, prevent, treat, diagnose, or cure Influenza Virus in people. We request that you take immediate action to cease the sale of any unlicensed, unapproved, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of Influenza Virus.\u003C\u002Fp>\n\n\u003Cp>Some examples of the claims on your website that establish the intended use of your product and misleadingly represent it as safe and\u002For effective for the prevention of Influenza Virus include:\u003C\u002Fp>\n\n\u003Cp>• “FLUZALP™ Quadrivalent is an inactivated Influenza vaccine indicated for active immunization against Influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUZALP QUADRIVALENT is approved for use in persons 4 years of age and older.”\u003C\u002Fp>\n\n\u003Cp>• “The quadruple strain formula provides protection for up to 6 months*. The product’s dosage form is injection, suspension and is administered via intramuscular form.”\u003C\u002Fp>\n\n\u003Cp>• “Each batch of these vaccines is then tested by FDA for Quantity, Quality and Efficacy before being release [sic] into the market.”\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to correct any violations of the FD&amp;C Act, the PHS Act, and FDA’s implementing regulations. This letter is not meant to be an all-inclusive list of violations that exist in connection with your product or operations. It is your responsibility to ensure that you and your products fully comply with the law.\u003C\u002Fp>\n\n\u003Cp>We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your product as safe and effective for an Influenza Virus-related use for which it has not been licensed by FDA and that you do not make claims that misbrand the product in violation of the FD&amp;C Act. \u003Cstrong>Within 48 hours, please send an email to CBERDCMRecommendations@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which your product is exported to the United States that FDA considers your product referenced above to be an unapproved and misbranded product that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Mary A. Malarkey\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Biologics Quality\u003Cbr>\nCenter for Biologics Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nHerman Cardenas\n\nDavati Medical Supply LLC\n\n3121 Eagles Nest St., Suite 120\n\nRound Rock, TX 78665\n\nUnited States\n\ncontact@davatimedical.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research\n\nUnited States\n\nCBER 21-02\n\nWARNING LETTER\n\nDate: June 25, 2021\n\nRE: Unapproved and Misbranded Product Related to Influenza Virus\n\nThis is to advise you that the United States Food and Drug Administration (FDA) has reviewed your website at www.davatimedical.com, on June 22, 2021. Your website directs consumers to contact you to purchase FLUZALP® QUADRIVALENT, Influenza Vaccine, which you represent is manufactured by Anzalp Pharmasolutions Pvt. Ltd. The FDA has observed that you offer this influenza vaccine product for sale in the United States and that the product is intended to mitigate, prevent, treat, diagnose, or cure Influenza Virus, commonly referred to as “the Flu”, in people.\n\nBased on our review, this product is an unapproved new drug under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355. Furthermore, this product is a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of this product into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).\n\nYour product is also an unlicensed biological product under section 351 of the Public Health Service Act (PHS Act), 42 U.S.C. § 262. In order to lawfully market a drug that is also a biological product, a valid biologics license must be in effect under the PHS Act. 42 U.S.C. § 262(a). Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations. 21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312. Your product is not the subject of an approved biologics license application (BLA) nor is there an IND in effect for your product.\n\nFDA is taking urgent measures to protect consumers from certain products that, without licensure, approval, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure Influenza Virus in people. As described in this letter, you offer for sale a product that is intended to mitigate, prevent, treat, diagnose, or cure Influenza Virus in people. We request that you take immediate action to cease the sale of any unlicensed, unapproved, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of Influenza Virus.\n\nSome examples of the claims on your website that establish the intended use of your product and misleadingly represent it as safe and\u002For effective for the prevention of Influenza Virus include:\n\n• “FLUZALP™ Quadrivalent is an inactivated Influenza vaccine indicated for active immunization against Influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUZALP QUADRIVALENT is approved for use in persons 4 years of age and older.”\n\n• “The quadruple strain formula provides protection for up to 6 months*. The product’s dosage form is injection, suspension and is administered via intramuscular form.”\n\n• “Each batch of these vaccines is then tested by FDA for Quantity, Quality and Efficacy before being release [sic] into the market.”\n\nYou should take immediate action to correct any violations of the FD&C Act, the PHS Act, and FDA’s implementing regulations. This letter is not meant to be an all-inclusive list of violations that exist in connection with your product or operations. It is your responsibility to ensure that you and your products fully comply with the law.\n\nWe advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your product as safe and effective for an Influenza Virus-related use for which it has not been licensed by FDA and that you do not make claims that misbrand the product in violation of the FD&C Act. Within 48 hours, please send an email to CBERDCMRecommendations@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nPlease note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which your product is exported to the United States that FDA considers your product referenced above to be an unapproved and misbranded product that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at CBERDCMRecommendations@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMary A. Malarkey\n\nDirector\n\nOffice of Compliance and Biologics Quality\n\nCenter for Biologics Evaluation and Research\n\nU.S. Food and Drug Administration","Davati Medical Supply LLC","davati-medical-supply-llc-615530-06252021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdavati-medical-supply-llc-615530-06252021","2026-10-26T08:08:21.596641+00:00","2021-07-06","615530","Biologics","2021-10-14","Herman Cardenas","2026-08-20T02:59:22.938+00:00","2021-06-25",3,{"510k":79,"classification":80,"enforcement":81,"event":82,"event_backfill":83,"pma":84,"warning_letter":85},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]